Holen Sie sich die Stockscreener-App
2.175
1.60%
-0.015
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
Abcellera at Bloom Burton: Strategic Shift in Biotech Development By Investing.com - Investing.com UK
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - BioSpace
AbCellera (ABCL) Unveils Promising Preclinical Results for T-Cel - GuruFocus
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x C - GuruFocus
AbCellera reports promising preclinical TCE cancer therapy data - Investing.com
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 | ABCL Stock News - GuruFocus
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
KeyBanc Increases Price Target for AbCellera (ABCL) Amidst Econo - GuruFocus
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com India
Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com
Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World
Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com
Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK
Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat
1.72%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):